Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

被引：4
|
作者：
Das, Sunit [1 ,2 ]
Sahgal, Arjun [3 ]
Perry, James R. [4 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Hosp, Dept Radiat Oncol, Toronto, ON, Canada
[4] Univ Toronto, Sunnybrook Hosp, Div Neurol, Toronto, ON, Canada
来源：
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词：
glioblastoma; chemotherapy; temozolomide; lomustine (CCNU); radiation therapy; ADJUVANT TEMOZOLOMIDE; RADIOTHERAPY; CHEMOTHERAPY; CONCOMITANT; SURVIVAL; REPAIR;
D O I：
10.3389/fonc.2020.00066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
    Herrlinger, Ulrich
    Tzaridis, Theophilos
    Mack, Frederic
    Steinbach, Joachim Peter
    Schlegel, Uwe
    Sabel, Michael
    Hau, Peter
    Kortmann, Rolf-Dieter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Schnell, Oliver
    Baehr, Oliver
    Uhl, Martin
    Seidel, Clemens
    Tabatabai, Ghazaleh
    Kowalski, Thomas
    Ringel, Florian
    Schmidt-Graf, Friederike
    Suchorska, Bogdana
    Brehmer, Stefanie
    Weyerbrock, Astrid
    Renovanz, Miriam
    Bullinger, Lars
    Galldiks, Norbert
    Vajkoczy, Peter
    Misch, Martin
    Vatter, Hartmut
    Stuplich, Moritz
    Schaefer, Niklas
    Kebir, Sied
    Weller, Johannes
    Schaub, Christina
    Stummer, Walter
    Tonn, Joerg-Christian
    Simon, Matthias
    Keil, Vera C.
    Nelles, Michael
    Urbach, Horst
    Coenen, Martin
    Wick, Wolfgang
    Weller, Michael
    Fimmers, Rolf
    Schmid, Matthias
    Hattingen, Elke
    Pietsch, Torsten
    Coch, Christoph
    Glas, Martin
    LANCET, 2019, 393 (10172): : 678 - 688
  • [2] Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
    Tremont-Lukats, Ivo W.
    Teh, Bin S.
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S589 - S591
  • [3] Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
    Weller, Johannes
    Tzaridis, Theophilos
    Mack, Frederic
    Steinbach, Joachim Peter
    Schlegel, Uwe
    Hau, Peter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Baehr, Oliver
    Uhl, Martin
    Seidel, Clemens
    Tabatabai, Ghazaleh
    Brehmer, Stefanie
    Bullinger, Lars
    Galldiks, Norbert
    Schaub, Christina
    Kebir, Sied
    Stummer, Walter
    Simon, Matthias
    Fimmers, Rolf
    Coch, Christoph
    Glas, Martin
    Herrlinger, Ulrich
    Schaefer, Niklas
    LANCET ONCOLOGY, 2019, 20 (10): : 1444 - 1453
  • [4] PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
    Herrlinger, Ulrich
    Tzaridis, Theophilos
    Mack, Frederic
    Steinbach, Joachim
    Schlegel, Uwe
    Sabel, Michael
    Hau, Peter
    Kortman, Rolf-Dieter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Schnell, Oliver
    Baehr, Oliver
    Uhl, Martin
    Tabatabai, Ghazaleh
    Ringel, Florian
    Schmidt-Graf, Friederike
    Brehmer, Stefanie
    Weyerbrock, Astrid
    Bullinger, Lars
    Vajkoczy, Peter
    Vatter, Hartmut
    Schaefer, Niklas
    Kebir, Sied
    Weller, Johannes
    Stummer, Walter
    Simon, Matthias
    Keil, Vera
    Nelles, Michael
    Fimmers, Rolf
    Pietsch, Torsten
    Hattingen, Elke
    Coch, Christoph
    Glas, Martin
    NEURO-ONCOLOGY, 2017, 19 : 13 - 14
  • [5] QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA
    Weller, Johannes
    Tzaridis, Theophilos
    Steinbach, Joachim
    Schlegel, Uwe
    Hau, Peter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Baehr, Oliver
    Uhl, Martin
    Seidel, Clemens
    Tabatabai, Ghazaleh
    Bullinger, Lars
    Galldiks, Norbert
    Schaub, Christina
    Stummer, Walter
    Simon, Matthias
    Fimmers, Rolf
    Matthias, Schmid
    Coch, Christoph
    Glas, Martin
    Herrlinger, Ulrich
    Schaefer, Niklas
    NEURO-ONCOLOGY, 2018, 20 : 218 - 219
  • [6] Combination Therapy of Lomustine and Temozolomide in Patients with newly diagnosed Glioblastoma with methylated MGMT Promotor
    Lenzen, Julia
    Feldmann, H. J.
    ONKOLOGE, 2019, 25 (12): : 1118 - 1120
  • [7] LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT
    Weller, Johannes
    Zeyen, Thomas
    Schlegel, Uwe
    Lazaridis, Lazaros
    Werner, Jan-Michael
    Onken, Julia
    Zeiner, Pia
    Drexler, Richard
    Hau, Peter
    Seidel, Clemens
    Grosse, Lucia
    Clusmann, Hans
    Sabel, Michael
    Ringel, Florian
    Pichler, Josef
    Grauer, Oliver
    Hundsberger, Thomas
    Schnell, Oliver
    Mair, Maximilian J.
    Uhl, Martin
    Schmidt-Graf, Friederike
    Glas, Martin
    Galldiks, Norbert
    Unteroberdoerster, Meike
    Steinbach, Joachim
    Ricklefs, Franz
    Renovanz, Mirjam
    Delev, Daniel Ivanov
    Turgut, Merih O.
    Flesch, Oliver R.
    Cipriani, Debora
    Preusser, Matthias
    Kebir, Sied
    Misch, Martin
    Goldbrunner, Roland
    Westphal, Manfred
    Tabatabai, Ghazaleh
    Schaefer, Niklas
    Schneider, Matthias
    Vatter, Hartmut
    Giordano, Frank
    Schaub, Christina
    Herrlinger, Ulrich
    NEURO-ONCOLOGY, 2022, 24 : 71 - 71
  • [8] Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
    Wen, Patrick Yung
    Rodon, Jordi A.
    Mason, Warren
    Beck, Joseph T.
    DeGroot, John
    Donnet, Valerie
    Mills, David
    El-Hashimy, Mona
    Rosenthal, Mark
    ESMO OPEN, 2020, 5 (04)
  • [9] Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
    Patil, Vijay M.
    Menon, Nandini
    Chatterjee, Abhishek
    Tonse, Raees
    Choudhari, Amit
    Mahajan, Abhishek
    Puranik, Ameya D.
    Epari, Sridhar
    Jadhav, Monica
    Pathak, Shruti
    Peelay, Zoya
    Walavalkar, Rutuja
    Muthuluri, Hemanth K.
    Krishna, Madala Ravi
    Chandrasekharan, Arun
    Pande, Nikhil
    Gupta, Tejpal
    Banavali, Shripad
    Jalali, Rakesh
    ECLINICALMEDICINE, 2022, 49
  • [10] POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL
    Zeyen, Thomas
    Paech, Daniel
    Weller, Johannes
    Schaefer, Niklas
    Tzaridis, Theophilos
    Duffy, Cathrina
    Nitsch, Louisa
    Schneider, Matthias
    Steinbach, Joachim
    Hau, Peter
    Schlegel, Uwe
    Seidel, Clemens
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Zeiner, Pia
    Tabatabai, Ghazaleh
    Galldiks, Norbert
    Stummer, Walter
    Hattingen, Elke
    Tabatabai, Ghazaleh
    Galldiks, Norbert
    Stummer, Walter
    Hattingen, Elke
    Glas, Martin
    Radbruch, Alexander
    Herrlinger, Ulrich
    Schaub, Christina
    NEURO-ONCOLOGY, 2022, 24 : 169 - 170
12345